Canvuparatide not checked
MBX Biosciences · MBX 2109 · of MBX 2109 - by
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “• Drug per vial: Each DDC contains 1 vial of lyophilized drug product. The reconstituted strengths are 400 μg/mL, 600 μg/mL, 800 μg/mL, 1000 μg/mL, 1200 μg/mL, 1400 μg/mL, and 1600 μg/mL.”In the company’s words, NCT07699471 on ClinicalTrials.gov
- Tested for
- Hypoparathyroidism (2 trials)
- Main trialPhase 3
- “The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).”In the company’s words, NCT07699471 on ClinicalTrials.gov
- Other names
- MBX 2109 · of MBX 2109 - by
Other drugs for Hypoparathyroidism
- PalopegteriparatideAscendis Pharma A/S · Phase 3
- EncaleretCalcilytix Therapeutics, Inc., a BridgeBio company · Phase 3
- EneboparatideAlexion Pharmaceuticals, Inc. · Phase 3
- AMOR-1Amorphical Ltd. · Phase 2
- EXT608Extend Biosciences Inc. · Phase 2
Coming up2
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jan 2028 | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism | |
| Phase 2Active, not recruiting | May 2028 | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | |
| Phase 2Completed | 23 May 2025 | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism | |
| Phase 1Completed | 20 Jun 2023 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects | |
| Phase 1Completed | 4 Sep 2025 | Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026